Know Cancer

or
forgot password


Phase 2
70 Years
N/A
Open (Enrolling)
Both
Lung Cancer

Thank you

Trial Information


Inclusion Criteria:



- Signed informed consent form

- Age ≥70 years

- Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1

- Histologically or cytologically confirmed lung cancer

- Did not receive bisphosphonate treatment

Exclusion Criteria:

- Appear relapse and metastasis

- receive other bisphosphonate treatment

- Active or uncontrolled infection

- Pregnant or lactating women

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Progression-free survival(PFS)

Outcome Time Frame:

1 year

Safety Issue:

Yes

Principal Investigator

Wei Liu

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hebei Tumor Hospital

Authority:

China: Food and Drug Administration

Study ID:

HBTH201

NCT ID:

NCT01737216

Start Date:

November 2012

Completion Date:

December 2016

Related Keywords:

  • Lung Cancer
  • Aged
  • patients
  • Lung Neoplasms

Name

Location